格隆汇2月11日｜美泰(MAT.US)盘前暴跌超30%，报14.62美元。消息面上，公司预计全年利润低于预 期，且去年第四季度利润不及市场预期。 ...

格隆汇2月11日丨龙佰集团(002601.SZ)公布，为拓宽融资渠道、优化融资结构、降低融资成本，公司拟 向中国银行间市场交易商协会申请注册发行短期融资券，发行总额不超过人民币20亿元（含20亿元）。 发行期限：拟发行短期融资券的期限为每期最长不超过1年；募集资金用途：包括但不限于补充公司流 动资金、偿还银行贷款和其他符合规定的用途。 ...

格隆汇2月11日丨大北农(002385.SZ)公布，2026年1月控股公司生猪销售数量为47.12万头，销售收入 6.12亿元。其中销售数量环比增长1.16%，同比增长22.71%；销售收入环比增长1.16%，同比增 长-4.67%；销售均价12.48元/公斤。2026年1月，生猪销售数量同比增长主要是产能逐步释放所致。 ...

| 序号 | 交易营业部名称 | | 买入金额(万) | 占总成交比例 | | --- | --- | --- | --- | --- | | 1 | 深股通专用 | 959次 47.34% 2 | 35735.46 | 7.48% | | 2 | eastmoney.com 机构专用 | 2028次 41.86% | 8334.50 | 1.74% | | 3 | 机构专用 | 2028次 41.86% | 5798.35 | 1.21% | | 4 | 招商证券股份有限公司深圳益田路免税商务大厦证券营业部 | 45次 46.67% | 609.24 | 0.13% | | 5 | 机构专用 | 2028次 41.86% | 5729.90 | 1.20% | | | (买入前5名与卖出前5名)总合计: | | 93518.03 | 19.57% | 中钨高新(000657.SZ)今日涨停，换手率6.46%，成交额47.79亿元。龙虎榜数据显示，深股通买入3.57亿元，卖出5.05亿元，净卖出1.47亿元。上榜席位全天 买入9.35亿元，卖出8.16亿元，合计净买入1.19亿元。(格隆汇) | | 买入金额 ...

Core Viewpoint - China Energy has increased its stake in Wanrun Co., Ltd. to 24.82% of the total share capital, indicating a significant investment in the company [1] Group 1: Shareholding Changes - From January 7, 2026, to February 11, 2026, China Energy acquired a total of 9.22 million shares of Wanrun Co., Ltd. through centralized bidding [1] - As of February 11, 2026, China Energy holds 229 million shares, representing 24.82% of the company's total share capital [1] - China Energy's concerted action partner, China Energy Capital, holds 20.10 million shares, accounting for 2.18% of the total share capital [1] Group 2: Total Holdings - The combined shareholding of China Energy and its concerted action partner, China Energy Capital, amounts to 249 million shares, which is 27.00% of the total share capital [1] - The change in shareholding percentage by China Energy and its concerted action partner has reached a threshold of 1% as per relevant regulations [1]

Core Viewpoint - China General Nuclear Power Corporation (CGN) has successfully completed the issuance of its first and second phases of ultra-short-term financing bonds for 2026, with funds received on February 11, 2026 [1] Group 1: Financing Details - The ultra-short-term financing bond is named "China General Nuclear Power Co., Ltd. 2026 First Phase Ultra-Short-Term Financing Bond" [1] - The bond has a total issuance amount of 1 billion RMB [1] - The bond has a maturity period of 268 days, with a repayment date set for November 6, 2026 [1] - The coupon rate for the bond is 1.55% [1]

格隆汇2月11日丨*ST松发(603268.SH)公布，公司下属公司恒力造船（大连）有限公司（简称"恒力造 船"）15艘30.6万吨超大型原油运输船建造合同于近日签约生效，本次标的合同金额合计约17-20亿美 元。 ...

Core Viewpoint - The company has maintained a strong growth momentum in its aerospace engine components business, with significant overseas clients and a positive outlook for the future [1] Company Overview - The company's main overseas clients include major international commercial aircraft engine manufacturers such as GE Aviation, Pratt & Whitney (P&W), Safran, and Rolls-Royce (RR) [1] Industry Outlook - The global aviation industry is expected to continue its growth, with Airbus delivering a total of 793 commercial aircraft in 2025 and achieving a record backlog of 8,754 orders by the end of 2025, including 1,124 wide-body aircraft [1] - Boeing is projected to deliver 600 commercial aircraft in the same year, with a backlog of 6,720 orders [1] - Both companies indicate that the demand for new aircraft globally will exceed 42,000 units over the next 20 years, suggesting that the international civil aviation manufacturing supply chain will benefit from this growth trend [1]

Core Viewpoint - The company, Shihua Technology (688093.SH), has received a new High-tech Enterprise Certificate from the Jiangsu Provincial Department of Science and Technology, Jiangsu Provincial Department of Finance, and the State Taxation Administration of Jiangsu Province, indicating its continued recognition as a high-tech enterprise [1] Group 1 - The certificate number is GR202532017131, and it was issued on December 19, 2025, with a validity period of three years [1] - This recognition follows the expiration of the company's previous High-tech Enterprise Certificate, which required a re-evaluation [1]

Core Viewpoint - The company, Yuandong Biotech (688513.SH), has participated in the procurement process for the continuation of drugs whose agreements from the national centralized procurement have expired, with 13 products proposed for selection in this round [1][2]. Group 1: Procurement Details - The company has submitted applications for the continuation procurement organized by Jiangsu, Henan, and Guangdong provinces [1]. - The proposed selected products include 12 that were previously selected in the first to eighth batches of national centralized procurement and one new product, Paricalcitol Injection [1]. - The sales revenue from these products is projected to be approximately 651.20 million yuan in 2024, accounting for 48.25% of the company's total revenue for that year [1]. Group 2: Impact on Revenue - For the period from January to September 2025, the expected sales revenue from these products is about 504.08 million yuan, representing 49.46% of the company's total revenue for that period [1]. - The procurement cycle will last until December 31, 2028, during which medical institutions will prioritize the selected drugs, ensuring the completion of agreed procurement volumes [2]. Group 3: Market Stability - The overall pricing of the procurement is expected to remain stable or decrease further, providing medical institutions with greater choice and ensuring continuity in clinical medication [2]. - Although some selected products may see a price decrease compared to original sales prices, the selection of 13 products allows the company to maintain its market share and enhance the accessibility of these drugs [2].